1154740-69-8

Upstream product

• 615-74-7 2-chloro-5-methylphenol 
• 101623-40-9 1-chloro-4-methyl-2-(prop-2-en-1-yloxy)benzene 

Downstream Products

• 1154740-70-1 6-chloro-2-(3-hydroxypropyl)-3-methylphenol 
• 1310800-52-2 (E)-6-chloro-3-methyl-2-(prop-1-enyl)phenol 
• 1310800-55-5 3-bromo-5-chloro-6-hydroxy-2-methylbenzaldehyde 
• 1310800-59-9 3-bromo-5-chloro-6-methoxy-2-methylbenzaldehyde 
• 153782-74-2 3-chloro-2-hydroxy-6-methylbenzaldehyde 
• 1154740-71-2 8-chloro-5-methyl-3,4-dihydro-2H-1-benzopyran 
• 1154740-72-3 6-bromo-8-chloro-5-methyl-3,4-dihydro-2H-1-benzopyran 
• 1596367-48-4 methyl 2-[3-benzyloxy-6-methyl-2-[5-methyl-(3,4-dihydro-2H-1-benzopyran-6-yl)]]-2-(tert-butoxy)acetate 
• 1596367-49-5 methyl 2-(tert-butoxy)-2-[3-hydroxy-6-methyl-2-[5-methyl-(3,4-dihydro-2H-1-benzopyran-6-yl)]phenyl]acetate 

Relevant academic research and scientific papers

Inhibitors of viral replication, their process of preparation and their therapeutical uses

The present invention relates to compounds of formula (I), their use in the treatment or the prevention of viral disorders, including HIV. wherein R1, R2, R3 and R4 are as included in the claims.

INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES

Inhibitors of viral replication of formula (I), their process of preparation and their therapeutical uses. The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.

Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximes

In a continuing effort to improve the subtype selectivity and agonist potency of estrogen receptor β (ERβ) ligands, we have designed and developed a thus far unexplored structural series obtained by molecular refinements of monoaryl-substituted salicylaldoximes (Salaldox B). The most interesting compounds in this series (2c, d) show remarkably high ERβ-binding affinities, with Ki values reaching the sub-nanomolar range (Ki = 0.38 nM for 2c and 0.57 nM for 2d), and have very high levels of ERβ-subtype selectivity. Both compounds show a potent full agonist character on ERβ (EC50 = 0.23 nM for 2c and 1.3 nM for 2d). Furthermore, 2d shows a remarkable functional subtype selectivity, with a β/α transcription potency ratio 50-fold higher than that of estradiol.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula I : wherein c, R2, R3, R4, R5, R6, R7 and R8 are defined herein, are useful as inhibitors of HIV replication.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula (I): wherein R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of formula (I): wherein c, X, Y, R2, R4 and R5 are defined herein, are useful as inhibitors of HIV replication.

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

The present invention relates to compounds of formula (I) wherein c, X, Y, R2, R3, R4 and R6 are as defined herein, compositions and uses thereof for treating human immunodeficiency virus (HIV) infection. In particular, the present invention provides novel inhibitors of HIV integrase, pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HIV infection